Efikasi dan Keamanan dari Pancreatic Enzyme Replacement Therapy pada Pasien Cystic Fibrosis : Sebuah Kajian Sistematis

Efficacy and Safety of Pancreatic Replacement Therapy (PERT) for patient with Cystic Fibrosis: A Systematic Review

Penulis

Kata Kunci:

Cystic Fibrosis, pancreatic insufficiency, pancreatic enzyme replacement therapy (PERT), efikasi, keamanan

Abstrak

Sekitar 80-90% pasien cystic fibrosis akan mengalami pancreatic insuffiency. Keadaan ini akan menyebabkan terjadinya malabsorpsi lemak dan protein dan akan berpengaruh pada status nutrisi dari pasien. Terapi dari terjadinya pancreatic insufficiency ini adalah dengan pemberian pancreatic enzyme replacement therapy (PERT) untuk meningkatkan absorpsi dari lemak dan juga protein pada pasien cystic fibrosis. Tujuan dari kajian sistematis ini adalah untuk mengetahui efikasi dan keamanan dari pemberian terapi PERT pada pasien yang mengalami pancreatic insufficiency pada pasien cystic fibrosis sehingga dapat dijadikan acuan atau pedoman dalam pemberian terapi PERT. Proses penelusuran pustaka melalui PUBMED dan Cohcrane Library menggunakan kata kunci PERT dan Cystic Fibrosis dengan Boolean operator “AND”. Penelitian yang terpilih sebanyak 14 dengan kriteria berupa RCT, pasien segala usia, pasien cystic fibrosis dengan pancreatic insufficiency, dan  membandingkan PERT dengan plasebo atau formulasi lain. Dari empat belas penelitian semua studi memperlihatkan peningkatan % CFA dari pemberian terapi PERT. Peningkatan % CFA dari semua studi mencapai rentang > 60% sampai > 80%. Studi yang membandingkan sediaan PERT dengan plasebo menunjukan hasil bahwa PERT mampu meningkatankan % CFA menjadi > 70% sementara plasebo memiliki % CFA sekitar 40% dan pemberian terapi PERT dinilai relatif aman dan dapat ditoleransi oleh pasien dengan cystic fibrosis.

Referensi

1. Boeck KD. 2020. Cystic Fibrosis in the year 2020 : A disease with a new face. Acta Pediatrica. 109:893-899.

2. Ahmed S, Cheok G, Goh AE, Han A, Hong SJ, Indawati W, et. al. 2020. Cystic Fibrosis in Asia.Pediatr Respirol Crit Care Med. 4:8-12.

3. Patel SD, Bono TR, Rowe SM, et. al. 2020. CFTR targeted therapies : Recent advances in cystic Fibrosis and Possibilities in other disease of the airways. Eur Respi Rev. 20: 190068.

4. Baker SS. 2008. Delayed release pancrealipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis. Therapeutic and Clinical Risk Management. 4(5) 1079-1084.

5. Capurso G, Traini M, Piciucchi M, Signoretti M, Arcidiacono PG. 2019. Exocrine pancreatic insufficiency : Prevalence, Diagnosis and Management. Clinical and experimental Gastroenterology. 12 129-139.

6. Stalling V, Stark L, Robinson K, Feranchak A, Quinton H. 2008. Evidence-based practice recommendation for nutrition-related management of children and adults eith cystic fibrosis and pancreatic insufficiency : results of systematic reviewe. Journal of the American Dietic Association. 108 (5):832-9.

7. Borowitz D, Baker SS, Duffy L. 2004. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr. 145:322-6.

8. Laniro G, Pecere S, Giorgio V. 2016. Digestive enzyme supplementation in gastrointestinal disease. Current drug metabolism. 17:187-193.

9. Borowitz D, Goss CH, Limauro S, Cohen M, Casey S et al. 2005. A phase 2 study of Theraclec-total enzymes in CF patients with pancreatic insufficiency (PI). Pediatric Pulmonology. 28.

10. Stead RJ, Skypala I, Hodson ME, Batten JC. 1987. Enteric coated microspheres of pancreatin in the treatment of cystic fibrosis: comparison with a standard enteric coated preparation. Thorax. 42(7):533-7.

11. Bowler IM, Wolfe SP, Owens HM, Sheldon TA, Littlewood JM, Walters MP. 1993. A double blind lipase for lipase comparion of a high lipase and standards pancreatic enzyme preparation in cystic fibrosis. Archives od Disease in Childhood. 68 : 227-230.

12. Borowitz D, Goss CH, Limauro S, Konstan MW, Blake K, Casey S, et al. 2006. Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. J Pediatr. 149(5):658-62.

13. Borowitz D, Stevens C, Brettman LR, Campion M, Chatfield B, Cipolli M, et al. 2011. International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. J Cyst Fibros. 10(6):443-52.

14. Graff GR, Maguiness K, McNamara J, Morton R, Boyd D, Beckmann K, et al. 2010. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study. Clin Ther. 32(1):89-103.

15. Konstan MW, Liou TG, Strausbaugh SD, Ahrens R, Kanga JF, Graff GR, et al. 2010. Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis. Gastroenterol Res Pract. 898193.

16. Heubi JE, Schaeffer D, Ahrens RC, Sollo N, Strausbaugh S, Graff G, et al. 2016. Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis: A Randomized Controlled Clinical Trial. J Pediatr. 176:156-61 e1.

17. Konstan MW, Stern RC, Trout JR, Sherman JM, Eigen H, Wagener JS, et al. 2004. Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy. Aliment Pharmacol Ther. 20(11-12):1365-71.

18. Konstan MW, Accurso FJ, Nasr ZS, Ahrens RC, Graff GR.. 2013. Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis.Clinical Investigation. 3(8), 723-729.

19. Mischler EH, Parrell S, Farrell PM, Odell GB. 1982. Comparion of effectiveness of pancreatic enzyme preparation in cystic fibrosis. Am J Dis Child. 136: 1060-1063.

20. Taylor CJ, Thieroff-Ekerdt R, Shiff S, Magnus L, Fleming R, Gommoll C. 2016. Comparison of two pancreatic enzyme products for exocrine insufficiency in patients with cystic fibrosis. J Cyst Fibros. 15(5):675-80.

21. Trapnell BC, Maguiness K, Graff GR, Boyd D, Beckmann K, Caras S. 2009. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros. 8(6):370-7.

22. Trapnell BC, Strausbaugh SD, Woo MS, Tong SY, Silber SA, Mulberg AE, et al. 2011. Efficacy and safety of PANCREAZE(R) for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros. 10(5):350-6.

23. Wooldridge JL, Heubi JE, Amaro-Galvez R, Boas SR, Blake KV, Nasr SZ, et al. 2009. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J Cyst Fibros. 8(6):405-17.

24. Taylor JR, Gardner TB, Waljee AK, Dimagno MJ, Schoenfeld PS. 2009. Systematic review : efficacy and safety of pancreatic enzyme supplements for exocrine pancreatic insufficiency. Alimentary Pharmacology & Therapeutics. (31), 57-72.

Unduhan

Diterbitkan

2021-08-31

Terbitan

Vol 3 No 4 (2021): J. Sains Kes.

Bagian

Review

Cara Mengutip

Efikasi dan Keamanan dari Pancreatic Enzyme Replacement Therapy pada Pasien Cystic Fibrosis : Sebuah Kajian Sistematis: Efficacy and Safety of Pancreatic Replacement Therapy (PERT) for patient with Cystic Fibrosis: A Systematic Review. (2021). Jurnal Sains Dan Kesehatan, 3(4), 620–632. https://jsk.ff.unmul.ac.id/index.php/JSK/article/view/523

Artikel paling banyak dibaca berdasarkan penulis yang sama